Clinical Trial Update: Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

Open-label long-term safety study of Certolizumab Pegol (CZP) in patients with rheumatoid arthritis completed; results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Certolizumab pegol (certolizumab pegol)

Snippet

Sponsor: UCB Pharma | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2012-07-09